Results

Total Results: 1,187 records

Showing results for "week".

  1. effectivehealthcare.ahrq.gov/sites/default/files/12_pregnancy_potential_high_impact_june_2012.pdf
    January 01, 2012 - by week,” which is a Web-based information venue requiring fast Internet connectivity. … the procedure is intended to correct the defect in the fetus, typically between the 19th and 26th week … Available: http://www.mayoclinic.com/health/pregnancy- week-by-week/MY00331. 14. Pregnancy. … prenatalcare.html http://www.nlm.nih.gov/medlineplus/prenatalcare.html http://www.mayoclinic.com/health/pregnancy-week-by-week … /MY00331 http://www.mayoclinic.com/health/pregnancy-week-by-week/MY00331 http://www.marchofdimes.com/
  2. Layout 1 (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/gerd-2005_executive.pdf
    January 01, 2005 - Layout 1 Background Gastroesophageal reflux disease (GERD), defined as weekly heartburn and/or acid regurgitation, is one of the most common health conditions affecting older Americans. Direct costs attributable to GERD were estimated to be $10 billion in the United States in 2000. Some patients have frequent, sever…
  3. effectivehealthcare.ahrq.gov/sites/default/files/implementation-package-unhealthy-alcohol-use-final.pdf
    September 01, 2018 - Heavy drinking among U.S. adults, 2016: >14 drinks per week for men or >7 drinks per week for women. … Institute on Alcohol Abuse and Alcoholism recommends no more than 4 drinks per day and 14 drinks per week … Heavy drinking among U.S. adults, 2016: >14 drinks per week for men or >7 drinks per week for women … For women and anyone 65 and older, they recommend no more than 3 drinks per day and 7 drinks per week … Skyy answers that she has up to 5 mixed vodka drinks in a day at least 2-3 days a week.
  4. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-evidence-summary-2022-update_0.pdf
    January 01, 2022 - Evidence Summary_Comparative Effectiveness Review No. 250_Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2022 Update Comparative Effectiveness Review Number 250 Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2022 Update Evide…
  5. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-234-headaches-pregnancy-revised-comments.pdf
    November 12, 2020 - posted to the EHC Program Web site or AHRQ Web site in draft form for public comment for a 3- to 4-week
  6. effectivehealthcare.ahrq.gov/sites/default/files/related_files/evidence-summary-cer-202-bronchial-thermoplasty-asthma.pdf
    December 01, 2017 - BT-treated patients than in patients receiving sham treatment and/or standard care during the 12-week
  7. effectivehealthcare.ahrq.gov/sites/default/files/related_files/depression-treatment-ssri_surveillance.pdf
    January 01, 2013 - adults 18 to 70 years old Augmentation with exercise Exercise expending 16 kcal per kg per week
  8. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-executive-summary-2023-update.pdf
    January 01, 2023 - Executive Summary - Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2023 Update Comparative Effectiveness Review Number 250 Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2023 Update Executive Summary Main Points …
  9. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-211-rheumatoid-arthritis-disposition-comments.pdf
    December 20, 2018 - This review was posted for 52 days with a 1-week holiday-related extension. … We have added the 24-week primary outcomes to the Results section as suggested. … group than for the MTX group at week 104 (p=0.038), but not at week 52 (p=NS). … At week 104, Thank you for the information. … 24 with Actemra combination therapy and were maintained through week 52.
  10. effectivehealthcare.ahrq.gov/sites/default/files/related_files/psoriasis-chronic_disposition-comments.pdf
    November 27, 2012 - effectiveness research review is posted to the EHC Program Web site in draft form for public comment for a 4-week … A 52- week trial comparing briakinumab with methotrexate in patients with psoriasis. … It should be acknowledged that it is commonplace for dermatologists to compare 12-week response rates … other end of the spectrum is phototherapy, which requires 2-3 visits to the doctor’s office each week … PASI should be given for all time points, i.e. baseline, week 12 and week 24.
  11. effectivehealthcare.ahrq.gov/sites/default/files/diabetes-update-2015_disposition-comments.pdf
    January 01, 2015 - Each research review is posted to the EHC Program Web site in draft form for public comment for a 4-week … Hollander at al. evaluated Saxagliptin added to TZD to assess efficacy at week 24. … ) extension of a 52-week randomised controlled trial. … study 52 week addition of DeFronzo 2009 data is from 24 week study 52 week This data was included … Nauck 2011 reported 52 Week data Nauck 2014 reported 104 week data We have fixed this reference.
  12. effectivehealthcare.ahrq.gov/sites/default/files/related_files/insomnia_disposition-comments.pdf
    December 30, 2015 - Each research review is posted to the EHC Program Web site in draft form for public comment for a 4-week … It is open to debate whether two week and four week durations are really so different in this context … All of that said, two week studies were included in the previous meta-analyses. … The zolpidem was supplied 3-5 times per week and contrasted with placebo. … 12 when treatment was discontinued to 53% at week 16.
  13. effectivehealthcare.ahrq.gov/sites/default/files/pdf/mat-retention-strategies-rapid-review-1.pdf
    August 01, 2020 - prison (3) in an OTP or (4) in the CHC Post-release: titrated dose to 8 mg/day, then 16 mg 3x/week … One time per week based on adherence the prior week. … One time per week based on adherence the prior week. … stabilization, 2 week taper) Retention: # of SMM (standard medical management) visits Phase 2 … : 16 weeks (12 week treatment, 4 week taper) SMM + ODC (opioid drug counseling) vs SMM alone
  14. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-surveillance-report-3_0.pdf
    May 01, 2022 - clinicaltrials.gov*".so. 16 11 or 12 or 13 or 14 or 15 17 10 not 16 Database: APA PsycInfo 1806 to January Week … THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week
  15. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-apps-a-e-surveillance-report-2-final_0_0.pdf
    March 01, 2022 - *".so. 16 11 or 12 or 13 or 14 or 15 17 10 not 16 Database: APA PsycInfo 1806 to September Week … oromucosal spray as add-on measure in patients with severe chronic I-15 pain: analysis of 12-week
  16. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2024-surv-rep-update-executive-sum.pdf
    January 01, 2024 - Executive summary_Comparative Effectiveness Review No. 250_Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2024 Update Comparative Effectiveness Review Number 250 Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2024 Update Exec…
  17. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-276-ocd-appendix-h.xlsx
    January 01, 2023 - Design Appendix H. Key Question 2 Predictors Table H-1. KQ2 Predictors of Treatment Efficacy PMID First Author Publication Year Extractor Study Name/Database/RCT PMID/Site Followup Duration N Mean Age (SD) Baseline CY-BOCS Score, Mean (SD) Intervention Type Pharmacolgical Interventions, Drug Class (e.g., SSRI) Phar…
  18. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2025-surv-rep-update-executive-sum.pdf
    January 01, 2025 - dose 23 mg THC/21 mg CBD daily Inhaled cannabis: Maximum of three 150 mg capsules per day in week
  19. effectivehealthcare.ahrq.gov/sites/default/files/13_pulmonary_potential_high_impact_june_2012.pdf
    January 01, 2012 - as 2 weeks, and a statistically significant treatment effect was reported to be maintained through week … Also through week 48, investigators reported, patients given ivacaftor were 55% less likely to have … second measurement that was 10.6 percentage points higher than patients treated with placebo through week … function were observed as early as 2 weeks, and a significant treatment effect was maintained through week … Also through week 48, patients given ivacaftor were 55% less likely to have a pulmonary exacerbation
  20. effectivehealthcare.ahrq.gov/sites/default/files/related_files/hepatitis-c-treatment-adherence_executive.pdf
    September 22, 2011 - The public was invited to comment on these Key Questions during a 4-week period.

Search the AHRQ Archive

Information and reports more than 5 years old may be found in the AHRQ Archive site.

Search Archive

Search Within A Specific AHRQ Site

You selected to view results for the following site: